ATE517633T1 - Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine - Google Patents

Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine

Info

Publication number: ATE517633T1
Authority: AT; Austria
Prior art keywords: vaccine; apc; composition; cellular; allogeneic
Prior art date: 2002-06-06

Application number

AT03730977T

Other languages

English (en)

Inventor

Alex Karlsson-Parra

Annacarin Wallgren

Bengt Andersson

Original Assignee

Immunicum Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-06

Filing date

2003-06-05

Publication date

2011-08-15

2002-06-06 Priority claimed from SE0201726A external-priority patent/SE523515C2/sv

2003-06-05 Application filed by Immunicum Ab filed Critical Immunicum Ab

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517633T1 publication Critical patent/ATE517633T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 4
230000001413 cellular effect Effects 0.000 title abstract 2
230000000735 allogeneic effect Effects 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000012258 culturing Methods 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
230000004927 fusion Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
238000002955 isolation Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000025113 myeloid leukemia Diseases 0.000 abstract 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000001890 transfection Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K40/4275—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Oncology (AREA)
Medicinal Chemistry (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)

AT03730977T 2002-06-06 2003-06-05 Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine ATE517633T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38589802P	2002-06-06	2002-06-06
SE0201726A SE523515C2 (sv)	2002-06-06	2002-06-06	Ny metod och komposition för framställning av ett cellulärt allogent vaccin
PCT/SE2003/000936 WO2003103707A1 (en)	2002-06-06	2003-06-05	New method and composition for producing a cellular allogeneic vaccine

Publications (1)

Publication Number	Publication Date
ATE517633T1 true ATE517633T1 (de)	2011-08-15

Family

ID=29738554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03730977T ATE517633T1 (de)	2002-06-06	2003-06-05	Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine

Country Status (8)

Country	Link
US (3)	US20050158328A1 (de)
EP (1)	EP1509244B1 (de)
AT (1)	ATE517633T1 (de)
AU (1)	AU2003241252A1 (de)
DK (1)	DK1509244T3 (de)
ES (1)	ES2369077T3 (de)
SI (1)	SI1509244T1 (de)
WO (1)	WO2003103707A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1712634A1 (de) *	2005-04-13	2006-10-18	Wittycell SAS	Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
US8563307B2 (en)	2009-02-24	2013-10-22	James Wang	Treatment of immunosuppression-related disorders
WO2010108908A1 (en) *	2009-03-24	2010-09-30	Transgene Sa	Biomarker for monitoring patients
US8679474B2 (en) *	2010-08-04	2014-03-25	StemBios Technologies, Inc.	Somatic stem cells
TWI571513B (zh)	2011-09-28	2017-02-21	幹細胞生物科技股份有限公司	體幹細胞及其製備方法
JP6495174B2 (ja)	2012-12-06	2019-04-03	ステムバイオステクノロジーズ，インコーポレイテッド	Ｌｇｒ５＋体性幹細胞
ES2548229T3 (es)	2012-12-18	2015-10-15	Immunicum Ab	Co-diferenciación de monocitos procedentes de donantes alogénicos
EP2746769A1 (de)	2012-12-21	2014-06-25	Stembios Technologies, Inc.	Verfahren zur Beurteilung der Wirkung einer Aktion basierend auf Stammzelldynamik auf eine Person
US12220451B2 (en)	2016-02-04	2025-02-11	Duke University	Cell-based vaccine compositions and methods of use
CN106645669B (zh) *	2016-11-15	2018-11-02	广东海洋大学	一种用于表征鲳鲹巨噬细胞吞噬微生物的方法
EP3460052B1 (de)	2017-09-20	2019-10-30	Immunicum AB	Verbesserte allogene dendritische zellen zur verwendung in der krebsbehandlung
CN112243382A (zh) *	2018-01-18	2021-01-19	南佛罗里达大学	死抗原刺激的未成熟异源性树突细胞作为疾病治疗剂
KR20220097875A (ko)	2019-09-03	2022-07-08	마이얼로이드 테라퓨틱스, 인크.	게놈 통합을 위한 방법 및 조성물
US10980836B1 (en)	2019-12-11	2021-04-20	Myeloid Therapeutics, Inc.	Therapeutic cell compositions and methods of manufacturing and use thereof
KR20230033647A (ko) *	2020-06-30	2023-03-08	멘두스 비.브이.	난소암 백신에서 백혈병 유래 세포의 용도
US12282027B2 (en)	2021-02-19	2025-04-22	University Of South Florida	High-throughput NMR approach for in-membrane protein ligand screening
BR112023023642A2 (pt)	2021-05-11	2024-01-30	Myeloid Therapeutics Inc	Métodos e composições para integração genômica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR960701208A (ko)	1993-03-16	1996-02-24	엔 엔 데이비스	바이러스 단백질에 의해 면역 반응을 자극하는 방법(stimulation of immune response by viral protein)
US5788963A (en) *	1995-07-31	1998-08-04	Pacific Northwest Cancer Foundation	Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5985270A (en) *	1995-09-13	1999-11-16	Fordham University	Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1998033527A2 (en) *	1997-01-31	1998-08-06	Cohen Edward P	Cancer immunotherapy with semi-allogeneic cells
US6251665B1 (en) *	1997-02-07	2001-06-26	Cem Cezayirli	Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
AU3102799A (en) *	1998-03-20	1999-10-11	Genzyme Corporation	Enhanced anti-tumor immunity
US20020025320A1 (en) *	1999-08-20	2002-02-28	Prosper Boyaka	Sialidases as mucosal adjuvants
US20020039583A1 (en)	1999-09-30	2002-04-04	Subjeck John R.	Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7794710B2 (en) *	2001-04-20	2010-09-14	Mayo Foundation For Medical Education And Research	Methods of enhancing T cell responsiveness

2003
- 2003-06-05 EP EP03730977A patent/EP1509244B1/de not_active Expired - Lifetime
- 2003-06-05 DK DK03730977.0T patent/DK1509244T3/da active
- 2003-06-05 WO PCT/SE2003/000936 patent/WO2003103707A1/en not_active Ceased
- 2003-06-05 US US10/516,915 patent/US20050158328A1/en not_active Abandoned
- 2003-06-05 AT AT03730977T patent/ATE517633T1/de not_active IP Right Cessation
- 2003-06-05 AU AU2003241252A patent/AU2003241252A1/en not_active Abandoned
- 2003-06-05 ES ES03730977T patent/ES2369077T3/es not_active Expired - Lifetime
- 2003-06-05 SI SI200332043T patent/SI1509244T1/sl unknown
2006
- 2006-11-24 US US11/603,819 patent/US8673296B2/en not_active Expired - Fee Related
2014
- 2014-01-27 US US14/164,518 patent/US20140141046A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003241252A1 (en)	2003-12-22
ES2369077T3 (es)	2011-11-25
US20070134219A1 (en)	2007-06-14
US8673296B2 (en)	2014-03-18
WO2003103707A1 (en)	2003-12-18
SI1509244T1 (sl)	2011-11-30
DK1509244T3 (da)	2011-10-24
US20050158328A1 (en)	2005-07-21
EP1509244B1 (de)	2011-07-27
US20140141046A1 (en)	2014-05-22
EP1509244A1 (de)	2005-03-02

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
SI1509244T1 (sl)	2011-11-30	Nov postopek in spojina za izdelavo celične alogenične vakcine
ATE260971T1 (de)	2004-03-15	Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE367833T1 (de)	2007-08-15	IN-VITRO-VERFAHREN ZUM HERSTELLEN EINER HOMOLOGEN ßGESTENTETENß TISSUE ENGINEERTEN HERZKLAPPE
DE60323340D1 (de)	2008-10-16	Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2004001007A3 (en)	2004-07-01	Buffered formulations for concentrating antibodies and methods of use thereof
DE602005019064D1 (de)	2010-03-11	Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
MX2009009225A (es)	2009-09-28	Endodermo definitivo.
ATE411380T1 (de)	2008-10-15	Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
WO2003059276A3 (en)	2004-03-04	Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
JP2004536615A5 (de)	2006-01-05
ATE512668T1 (de)	2011-07-15	Allogenes tumortherapeutikum
ATE501264T1 (de)	2011-03-15	Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
ES2141922T3 (es)	2000-04-01	Tiazepinonas de benzotiofeno, benzofurano e indol, oxazepinonas y diazepinonas usadas como inhibidores de la adherencia celular y del vih.
DE60042035D1 (de)	2009-05-28	Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
ATE444950T1 (de)	2009-10-15	Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
DE60334382D1 (de)	2010-11-11	Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
WO2007136760A3 (en)	2008-02-14	Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
DE60310748D1 (de)	2007-02-08	Verfahren zur homogenen masskultivierung von t-lymphozyten
DK1419240T3 (da)	2011-10-17	Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutika
RU2013140560A (ru)	2015-03-10	Композиции и способы для лечения во время не острых периодов после неврологического повреждения цнс
NO20053089D0 (no)	2005-06-23	Carbamidsyreestere med anticolinergisk virkning.
ATE544849T1 (de)	2012-02-15	Aktivierte dendritische zellen, therapieverfahren unter verwendung der dendritischen zellen sowie verfahren zur kultivierung von gamma-delta-t- zellen
ATE332905T1 (de)	2006-08-15	Verfahren zur herstellung von acylphosphinoxiden
ATE522543T1 (de)	2011-09-15	Verfahren zur herstellung von reifem, rekombinantem milben-i-allergen
ATE392413T1 (de)	2008-05-15	Verfahren zur herstellung von beta-alaninamiden